Risperidone
Approved · FDA / EMAAlso known as Perseris, RisperDAL, Rykindo, Uzedy+4 more
Perseris, RisperDAL, Rykindo, Uzedy, Risperidona, Rispéridone, 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-A)pyrimidin-4-one, Risperidonum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Label change: RISPERIDONE (ANDA076996)
Risperidone vs Cariprazine in Acute Mania a Head to Head Comparison of Efficacy vs Tolerability
Label change: RISPERIDONE (ANDA077494)
Cerebellar-cortical Circuitry and Prediction of Treatment Response in Early Psychosis
Effectiveness of Switching Antipsychotic Medications
Label change: RISPERIDONE (ANDA091384)
Label change: RISPERIDONE (ANDA079088)
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.
Evidence ↗Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Cerebellar-cortical Circuitry and Prediction of Treatment Response in Early Psychosis
"Re-examining Maintenance Antipsychotic Treatment in Schizophrenia: "Extended" Antipsychotic Dosing"
Risperidone vs Cariprazine in Acute Mania a Head to Head Comparison of Efficacy vs Tolerability
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Journal of the American Academy of Child and Adolescent Psychiatry2
- The New England journal of medicine2
- Acta psychiatrica Scandinavica1
- European archives of psychiatry and clinical neuroscience1
- European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology1
- International clinical psychopharmacology1
- Mittoux A4
- Peuskens J4
- Lieberman JA3
- Tanghøj P3
- Crocq MA2
- Everitt B2
- Findling RL2
- Frazier JA2
- Case Western Reserve University.1
- Centre Hospitalier1
- College of Physicians and Surgeons1
- Columbia University1
- Drs. McClellan and Hlastala are with the University of Washington1
- General Hospital Middelheim1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Acts on the same molecular target as Risperidone, with 3 overlapping disease areas.
Acts on the same molecular target as Risperidone, with 3 overlapping disease areas.
Acts on the same molecular target as Risperidone, with 3 overlapping disease areas.
Studied across 3 of the same disease areas as Risperidone in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.